Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Krogh

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Diabetes, Obesity & Metabolism|June 1, 2026
Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised IndividualsLiva S L Krogh, Maja B Hansen, Natasha C Bergmann, et al.
Diabetes Care|October 11, 2023
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled TrialCasper K Nielsen, Caroline C Øhrstrøm, Inas J K Houji, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 10, 2024
Danish and Swedish National Data Collections for Cancer - Solutions for RadiotherapyC E Olsson, S L Krogh, M Karlsson, et al.
European Journal of Endocrinology|January 18, 2023
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humansLiva S L Krogh, Kristine Henriksen, Signe Stensen, et al.
Diabetes Care|January 18, 2020
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 DiabetesNatasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, et al.
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 17, 2025
Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1M S Thomsen, E L Lorenzen, J Alsner, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Diabetes, Obesity & Metabolism|June 1, 2026
Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised IndividualsLiva S L Krogh, Maja B Hansen, Natasha C Bergmann, et al.
Diabetes Care|October 11, 2023
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled TrialCasper K Nielsen, Caroline C Øhrstrøm, Inas J K Houji, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 10, 2024
Danish and Swedish National Data Collections for Cancer - Solutions for RadiotherapyC E Olsson, S L Krogh, M Karlsson, et al.
European Journal of Endocrinology|January 18, 2023
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humansLiva S L Krogh, Kristine Henriksen, Signe Stensen, et al.
Diabetes Care|January 18, 2020
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 DiabetesNatasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, et al.
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 17, 2025
Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1M S Thomsen, E L Lorenzen, J Alsner, et al.
Pageof 1